Form 4: Director Sells GALT Shares Under 10b5-1 Plan
Insider Transaction Report
Galectin Therapeutics Director Harold H. Shlevin executed pre-planned sales of common stock after exercising multiple stock options.
Summary
- Director Harold H. Shlevin of Galectin Therapeutics Inc. (GALT) engaged in multiple transactions involving the exercise of stock options and subsequent sale of common stock on December 8 and 9, 2025.
- All transactions were conducted under a Rule 10b5-1 plan adopted on August 29, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on November 14, 2025.
- Shlevin exercised options to acquire a total of 171,790 shares of common stock at exercise prices ranging from $1.11 to $4.16 per share.
- Concurrently, Shlevin sold a total of 171,790 shares of common stock at weighted average sale prices ranging from $5.946 to $6.266 per share.
- Following these transactions, Shlevin's direct beneficial ownership of common stock is 11,206 shares.
- Shlevin also holds 73,210 derivative securities (stock options) after these transactions.
Sentiment
Score: 5
Explanation: The transactions represent a director exercising options and selling shares for profit, which is a neutral event in itself. The pre-planned nature (10b5-1) mitigates negative sentiment often associated with insider sales, but the reduction in direct common stock ownership could still be viewed with slight caution.
Positives
- The director realized significant profits by exercising options at lower prices and selling shares at higher market prices.
- Transactions were conducted under a Rule 10b5-1 plan, indicating pre-scheduled sales and not necessarily a reaction to new, non-public negative information.
Negatives
- A director selling a substantial number of shares (171,790 shares) could be perceived negatively by the market, even if pre-planned.
- The beneficial ownership of common stock decreased significantly from previous levels after the sales.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the director's sale of shares, even if pre-planned, as a signal, potentially leading to short-term price fluctuations.
- The transactions demonstrate the director's monetization of previously granted equity compensation.
Key Dates
| Date | Description |
|---|---|
| 06/30/2018 | First vesting date for some stock options. |
| 09/30/2018 | Second vesting date for some stock options. |
| 12/31/2018 | Final vesting date for some stock options. |
| 06/30/2021 | First vesting date for some stock options. |
| 12/31/2021 | Vesting date for multiple stock options. |
| 06/30/2022 | Vesting date for some stock options. |
| 12/31/2022 | Vesting date for multiple stock options. |
| 12/31/2023 | Vesting date for some stock options. |
| 12/31/2024 | Vesting date for multiple stock options. |
| 08/29/2025 | Date Rule 10b5-1 plan was adopted by the reporting person. |
| 12/08/2025 | Date of multiple stock option exercises and subsequent sales of common stock. |
| 12/09/2025 | Date of stock option exercise and subsequent sale of common stock. |
| 12/10/2025 | Signature date of the filing. |
| 05/22/2028 | Expiration date for some stock options. |
| 03/25/2031 | Expiration date for multiple stock options. |
| 01/24/2032 | Expiration date for some stock options. |
| 01/26/2033 | Expiration date for some stock options. |
| 01/24/2034 | Expiration date for some stock options. |
Keywords
Galectin Therapeutics, GALT, Harold H. Shlevin, Director, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Equity Sales, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.